×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BNTX – biontech se - american depositary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BNTX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/16
07:05 am
bntx
BioNTech (NASDAQ:BNTX) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating.
Low
Report
BioNTech (NASDAQ:BNTX) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating.
1/14
04:31 am
bntx
BioNTech Pivots Back to Oncology at JPM Conference, Teases 15 Phase III Readouts and $17B Cash Plan [Yahoo! Finance]
Low
Report
BioNTech Pivots Back to Oncology at JPM Conference, Teases 15 Phase III Readouts and $17B Cash Plan [Yahoo! Finance]
1/12
07:05 am
bntx
BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/12
06:45 am
bntx
BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference
Low
Report
BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference
12/18
04:45 am
bntx
BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field
Low
Report
BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field
12/11
07:03 pm
bntx
BioNTech SE (BNTX) is a Buy on Lung Cancer Treatment Prospects: Clear Street [Yahoo! Finance]
Low
Report
BioNTech SE (BNTX) is a Buy on Lung Cancer Treatment Prospects: Clear Street [Yahoo! Finance]
12/11
10:04 am
bntx
BioNTech (NASDAQ:BNTX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
BioNTech (NASDAQ:BNTX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/11
09:18 am
bntx
BioNTech (NASDAQ:BNTX) had its price target raised by analysts at Berenberg Bank from $150.00 to $155.00. They now have a "buy" rating on the stock.
Low
Report
BioNTech (NASDAQ:BNTX) had its price target raised by analysts at Berenberg Bank from $150.00 to $155.00. They now have a "buy" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
11/3/2025
06:45 am
BNTX
biontech se - american depositary shares
MISS
Report
-3.8%
biontech se - american depositary shares
8/4/2025
06:45 am
BNTX
biontech se - american depositary shares
MISS
Report
1.1%
biontech se - american depositary shares
5/5/2025
06:45 am
BNTX
biontech se - american depositary shares
BEAT
Report
-3.3%
biontech se - american depositary shares
3/10/2025
06:55 am
BNTX
biontech se - american depositary shares
BEAT
Report
-1.9%
biontech se - american depositary shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/14
06:01 am
bntx
Form 6-K BioNTech SE For: Jan 13
Low
Report
Form 6-K BioNTech SE For: Jan 13
1/12
06:58 am
bntx
Form 6-K BioNTech SE For: Jan 12
Low
Report
Form 6-K BioNTech SE For: Jan 12
1/6
06:03 am
bntx
Form 6-K BioNTech SE For: Jan 06
Low
Report
Form 6-K BioNTech SE For: Jan 06
12/18
04:15 pm
bntx
Form 6-K BioNTech SE For: Dec 18
Low
Report
Form 6-K BioNTech SE For: Dec 18
12/9
07:25 am
bntx
Form 6-K BioNTech SE For: Dec 09
Low
Report
Form 6-K BioNTech SE For: Dec 09
12/8
06:37 am
bntx
Form 6-K BioNTech SE For: Dec 06
Low
Report
Form 6-K BioNTech SE For: Dec 06
12/3
04:30 pm
bntx
Form 6-K BioNTech SE For: Dec 03
Low
Report
Form 6-K BioNTech SE For: Dec 03
11/28
07:11 am
bntx
Form 144 BioNTech SE Filed by: Tureci Ozlem
Low
Report
Form 144 BioNTech SE Filed by: Tureci Ozlem
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/17
Pfizer and BioNTech to Co-develop Potential COVID-19 Vaccine
57.1%
3/18 BioNTech (BNTX) Skyrockets on Coronavirus Vaccine Hopes; One Analyst Remains Cautious [Yahoo! Finance News] 30.5%
4/22 Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H1 2020 - ResearchAndMarkets.com 26.6%
3/16 BioNTech reports rapid progress on COVID-19 vaccine program to address global public health threat 25.1%
11/4 BioNTech SE (NASDAQ: BNTX) is now covered by analysts at Bank of America Corp. They set a "buy" rating and a $21.00 price target on the stock. 12.2%
1/3 Global Novel Vaccine Delivery Devices Industry Report 2019-2030 10.6%
2/3 BioNTech Announces Commencement of Public Offering of American Depositary Shares 9.7%
1/6 Genevant Sciences to Present at Biotech Showcase 2020 9.4%
3/26 Detailed Insights into In Silico/Computer-Aided Drug Discovery Services Market to 2030 - Elaborate Profiles of Key Industry Players - ResearchAndMarkets.com 8.6%
12/6 Precision Medicine Market: Industry Analysis and Detailed Profiles of Neon Therapeutics, Moderna, Inc, Merck & Co., Inc, Bayer AG, PERSONALIS INC, GENOCEA BIOSCIENCES, INC | Data Bridge Market Research 8.4%
3/18 BioNTech (BNTX) Skyrockets on Coronavirus Vaccine Hopes; One Analyst Remains Cautious [Yahoo! Finance News] 30.5%
4/22 Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H1 2020 - ResearchAndMarkets.com 26.6%
3/16 BioNTech reports rapid progress on COVID-19 vaccine program to address global public health threat 25.1%
11/4 BioNTech SE (NASDAQ: BNTX) is now covered by analysts at Bank of America Corp. They set a "buy" rating and a $21.00 price target on the stock. 12.2%
1/3 Global Novel Vaccine Delivery Devices Industry Report 2019-2030 10.6%
2/3 BioNTech Announces Commencement of Public Offering of American Depositary Shares 9.7%
1/6 Genevant Sciences to Present at Biotech Showcase 2020 9.4%
3/26 Detailed Insights into In Silico/Computer-Aided Drug Discovery Services Market to 2030 - Elaborate Profiles of Key Industry Players - ResearchAndMarkets.com 8.6%
12/6 Precision Medicine Market: Industry Analysis and Detailed Profiles of Neon Therapeutics, Moderna, Inc, Merck & Co., Inc, Bayer AG, PERSONALIS INC, GENOCEA BIOSCIENCES, INC | Data Bridge Market Research 8.4%
TOP News Decliners
3/18
German Billionaire Twins’ Investment In Biotech Firm Surges After Deal With Pfizer On Coronavirus Vaccine [Forbes]
-35.5%
3/19 Search for Coronavirus Vaccine Becomes a Global Competition [The New York Times] -23.1%
10/23 Global Personalized Cancer Vaccine Market, Clinical Trials & Future Outlook 2026 - ResearchAndMarkets.com -17.3%
4/22 Form 6-K BioNTech SE For: Apr 22 -15.7%
4/6 BioNTech SE (NASDAQ: BNTX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $59.00 price target on the stock. -15.6%
4/23 Pfizer Targets Summer For COVID-19 Vaccine Human Trials; Potential Treatment Also In The Works. [The Motley Fool] -14.1%
10/10 BioNTech Announces Pricing of Initial Public Offering -13.7%
3/16 BioNTech up 55% premarket on advancement of coronavirus vaccine [Seeking Alpha] -13.4%
4/9 Global Pharma, Biotech & Diagnostics Co-promotion & Co-marketing Partnering Terms & Agreements Report, 2014-2020 -11.7%
1/16 BioNTech to acquire Neon to strengthen global leadership position in T cell therapies -11.6%
3/19 Search for Coronavirus Vaccine Becomes a Global Competition [The New York Times] -23.1%
10/23 Global Personalized Cancer Vaccine Market, Clinical Trials & Future Outlook 2026 - ResearchAndMarkets.com -17.3%
4/22 Form 6-K BioNTech SE For: Apr 22 -15.7%
4/6 BioNTech SE (NASDAQ: BNTX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $59.00 price target on the stock. -15.6%
4/23 Pfizer Targets Summer For COVID-19 Vaccine Human Trials; Potential Treatment Also In The Works. [The Motley Fool] -14.1%
10/10 BioNTech Announces Pricing of Initial Public Offering -13.7%
3/16 BioNTech up 55% premarket on advancement of coronavirus vaccine [Seeking Alpha] -13.4%
4/9 Global Pharma, Biotech & Diagnostics Co-promotion & Co-marketing Partnering Terms & Agreements Report, 2014-2020 -11.7%
1/16 BioNTech to acquire Neon to strengthen global leadership position in T cell therapies -11.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: